|
|
Article: ALS Therapy Development Foundation Appoints Clinical Advisory Board; Leading ALS Researchers to Advise Nonprofit Biotechnology Company on Developing New Treatments for ALS.
- Article from:
- PR Newswire
- Article date:
- April 24, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEWTON, Mass. -- NEWTON, Mass., April 24 /PRNewswire/ -- The ALS Therapy Development Foundation (ALS-TDF) today announced the appointment of its Clinical Advisory Board (CAB), comprised of world-leading researchers in Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig's disease. Experts in researching, diagnosing and treating ALS, the group will provide scientific and strategic input on advancing ALS-TDF's drug development program.
"The establishment of our Clinical Advisory Board is a critical step in achieving our mission to develop effective treatments for people living with ALS," said James Heywood, ALS-TDF's Founding Director. "Our approach to drug ...